Document is current

Article History

Received: 11 April 2023

Accepted: 22 June 2023

First Online: 28 June 2023

Declarations

:

: Not applicable.

: Not applicable.

: DWT and CBN are designated inventors of Visual Patient, for which the University of Zurich and Koninklijke Philips N.V. hold various patents, patent applications, design protections, and trademarks. There are cooperation and licensing agreements with Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany; Koninklijke Philips N.V., Amsterdam, The Netherlands; Philips Research/Philips Electronics Nederland BV, Eindhoven, The Netherlands; Philips USA, Cambridge, MA, USA. Under these agreements, DWT receives research funding and DWT and CBN receive travel support, lecturing and consulting honoraria, and may receive royalties in the event of successful commercialization. DWT is a Philips Patient Safety Advisory Board member. DWT, CBN, and DRS are designated inventors of Visual Clot technology, for which the University of Zurich holds various patent applications, design protections, and trademarks. DWT, CBN, and DRS may receive royalties in the event of successful commercialization. DWT, CBN, TRR, and DRS are designated inventors of Visual Blood technology, for which the University of Zurich holds various patent applications, and design protections. DWT, CBN, DRS, and TRR may receive royalties in the event of successful commercialization. DWT and CBN receive travel support, lecturing and consulting honoraria from Instrumentation Laboratory, Bedford, MA, USA. DWT receives travel support, lecturing and consulting honoraria from Swiss Foundation for Anaesthesia Research, Zurich, Switzerland, and International Symposium on Intensive Care on Emergency Medicine, Brussels, Belgium. DRS’s academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Perioperative Medicine (SSAPM), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland. DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland. DRS received honoraria / travel support for consulting or lecturing from Alliance Rouge, Bern, Switzerland, Danube University of Krems, Austria, European Society of Anesthesiology and Intensive Care, Brussels, BE, International Foundation for Patient Blood Management, Basel, Switzerland, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Society for the Advancement of Blood Management, Mount Royal NJ, Alexion Pharmaceuticals Inc., Boston, MA, AstraZeneca AG, Baar, Switzerland, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, Baxter AG, Glattpark, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, CSL Vifor (Switzerland) Villars-sur-Glâne, Switzerland, CSL Vifor (International), St. Gallen, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Novo Nordisk Health Care AG, Zurich, Switzerland, Octapharma AG, Lachen, Switzerland, Pharmacosmos A/S, Holbaek, Denmark, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd, Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Takeda, Glattpark, Switzerland, Werfen, Bedford, MA, Zuellig Pharma Holdings, Singapore, Singapore. The other authors do not have any conflicts of interest.